516 related articles for article (PubMed ID: 20005365)
1. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
[TBL] [Abstract][Full Text] [Related]
2. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
3. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
4. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
[TBL] [Abstract][Full Text] [Related]
5. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
6. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
7. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
8. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
9. Where did we leave off in 2008? Conclusions from the 8th International Symposium.
Russ G
Transplant Proc; 2009; 41(6 Suppl):S27-30. PubMed ID: 19651292
[TBL] [Abstract][Full Text] [Related]
10. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
11. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
12. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Alberú J; Pascoe MD; Campistol JM; Schena FP; Rial Mdel C; Polinsky M; Neylan JF; Korth-Bradley J; Goldberg-Alberts R; Maller ES;
Transplantation; 2011 Aug; 92(3):303-10. PubMed ID: 21792049
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
14. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
[TBL] [Abstract][Full Text] [Related]
16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
17. New approaches to de novo immunosuppression and steroid elimination.
Lebranchu Y
Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
[TBL] [Abstract][Full Text] [Related]
18. Assessment of hypertension control in chronic kidney disease patients by ambulatory blood pressure monitoring.
Prakash S; Chibber SK; Prakash S; Pande DP; Joshi S; Gupta KK; Rana DS
J Assoc Physicians India; 2005 Sep; 53():769-74. PubMed ID: 16334620
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus in pediatric renal transplantation recipients.
Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
[TBL] [Abstract][Full Text] [Related]
20. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]